Worcester, MA, United States
Worcester, MA, United States

Time filter

Source Type

A live audio webcast will begin at 4:30 p.m. ET. The webcast link is available under the "Investors - Event Calendar" section of the Company's website, www.rxipharma.com.  The event may also be accessed by dialing toll-free in the United States: +1 844-376-4678. International participants may access the event by dialing: +1 209-905-5958.  An archive of the webcast will be available on the company's website approximately two hours after the presentation. RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs.  Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which has the ability to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.  RXi developed a robust RNAi therapeutic platform, including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology and cell-based immunotherapy.  RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies.  Additional information may be found on the Company's website, www.rxipharma.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-webcast-first-quarter-2017-financial-results-on-thursday-may-11-2017-300451367.html

SAN FRANCISCO, CA--(Marketwired - February 23, 2017) - RXi Pharmaceuticals Corp.'s ( : RXII) proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. Included in this interview is: RXi Pharmaceuticals Corp. The Life Sciences Report: Would you tell us about RXi Pharmaceuticals Corp.'s RNAi therapeutic platform and sd-rxRNA compounds, what they are and how they are differentiated from your competitors? Pam Pavco: RXi has developed a proprietary self-delivering RNAi platform, termed sd-rxRNA, in which we've altered and improved upon the modifications and the structure of the standard RNAi compound. This novel class of compounds has improved drug-like properties that are potent, stable and specific with built-in delivery properties and therefore do not require a delivery vehicle for local therapeutic applications. These improvements allow our compounds to be very efficiently taken up by cells. That is the one major differentiation between sd-rxRNA and RNAi compounds being used by other companies. The fact that sd-rxRNA is effectively taken up by cells means that sd-rxRNA is very amenable to use for disease areas where you can do local delivery. That has led to our selection of initial therapeutic areas, such as looking at the reduction of scarring in the skin and also the reduction of scarring in the eye, because you can deliver by direct application to both the skin and the eye. It also makes it perfect for the new area that we're now going into, cell-based immuno-oncology, because for cell therapy we will be delivering sd-rxRNA directly to cells ex vivo, that is, outside of the body. So it's a perfect way to deliver RNAi to the immune cells for these types of therapies. Continue reading this interview: RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. RXi Pharmaceuticals Corp. is a sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclaimers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Please see the end of the interview for the complete disclosure: RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology

— Age Related Macular Degeneration - Companies Involved in Therapeutics Development are 3SBio Inc, AC Immune SA, Achillion Pharmaceuticals Inc, Aciont Inc, Acucela Inc, AdAlta Ltd, Adverum Biotechnologies Inc, Aerie Pharmaceuticals Inc, Aerpio Therapeutics Inc, Alimera Sciences Inc, Alkeus Pharmaceuticals Inc, Allergan Plc, Allinky Biopharma, Alteogen Inc, Amakem NV, Amarna Therapeutics BV, Ampio Pharmaceuticals Inc, Amyndas Pharmaceuticals LLC, ANP Technologies Inc, Apellis Pharmaceuticals Inc, Apexigen Inc, Applied Genetic Technologies Corp, Astellas Pharma Inc, Benitec Biopharma Ltd, Biokine Therapeutics Ltd, BioMAS Ltd, Biomics Biotechnologies Co Ltd, Biophytis SAS, BLR Bio LLC, Boehringer Ingelheim GmbH, Caladrius Biosciences Inc, Catalyst Biosciences Inc, Cell Cure Neurosciences Ltd, Cell Medica Ltd, Charlesson LLC, Chong Kun Dang Pharmaceutical Corp, Cipla Ltd, Clanotech AB, Clearside BioMedical Inc, Coherus BioSciences Inc, Colby Pharmaceutical Company, Crinetics Pharmaceuticals Inc, Critical Pharmaceuticals Ltd, Daiichi Sankyo Company Ltd, Diffusion Pharmaceuticals Inc, Dong-A Socio Holdings Co Ltd, Eleven Biotherapeutics Inc., Elsalys Biotech SAS, Exonate Ltd, F. Hoffmann-La Roche Ltd, FirstString Research Inc, Foamix Pharmaceuticals Ltd, Formycon AG, Gene Techno Science Co Ltd, Genentech Inc, GenSight Biologics SA, GlaxoSmithKline Plc, Graybug Vision Inc, Grupo Ferrer Internacional SA, HanAll Biopharma Co Ltd, Huabo Biopharm Co Ltd, iCo Therapeutics Inc., Icon Bioscience Inc, Iconic Therapeutics Inc, Inception Sciences Inc, Innovent Biologics Inc, Intellect Neurosciences Inc, International Stem Cell Corp, Ionis Pharmaceuticals Inc, Jeil Pharmaceutical Co Ltd, Johnson & Johnson, Kala Pharmaceuticals Inc, Kodiak Sciences Inc, Lead Discovery Center GmbH, LeadArtis SL, M's Science Corp, Mabion SA, MacuCLEAR Inc, MeiraGTx Ltd, Mitotech SA, Mitsubishi Tanabe Pharma Corp, Mor Research Application Ltd, Navigen Pharmaceuticals Inc, Navya Biologicals Pvt Ltd, Neovacs SA, Neumedicines Inc, Neuroptis Biotech, Novartis AG, NovelMed Therapeutics Inc, Ocular Therapeutix Inc, Ohr Pharmaceutical Inc, Omeros Corp, Ophthotech Corp, Oxford BioMedica Plc, PanOptica Inc, Pfenex Inc, Pfizer Inc, Precision Ocular Ltd, Promedior Inc, pSivida Corp, QLT Inc, Ra Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, Retrotope Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, SanBio Inc, Santen Pharmaceutical Co Ltd, SciFluor Life Sciences LLC, Stealth BioTherapeutics Inc, Sucampo Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Sun Pharma Advanced Research Company Ltd, TRACON Pharmaceuticals Inc, TWi Pharmaceuticals Inc, Tyrogenex Inc, Wellstat Ophthalmics Corp and Xbrane Biopharma AB. Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs. The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 33, 11, 109 and 31 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively. Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Inquire more about this research at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=786897 Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology). • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/

News Article | December 16, 2016
Site: www.prnewswire.com

MARLBOROUGH, Mass., Dec. 16, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced the pricing of an underwritten public offering of securities for...

LOS ANGELES, Nov. 28, 2016 /PRNewswire/ -- StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Newscast with Pamela Pavco, Ph.D., Chief Development Officer for RXi Pharmaceuticals Corporation (NASDAQ: RXII) a clinical-stage company developing therapeutics that...

Khvorova A.,RXi Pharmaceuticals | Wolfson A.,University of Massachusetts Medical School
Nature Biotechnology | Year: 2012

An additional layer of RNA regulation in which RNAs encoded by genes and pseudogenes compete for microRNAs could offer new opportunities for oligonucleotide therapeutics. © 2012 Nature America, Inc. All rights reserved.

RXi Pharmaceuticals | Date: 2013-09-30

RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.

MARLBOROUGH, Mass., Nov. 10, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today reported its financial results for the third quarter ended September 30, 2016,...

MARLBOROUGH, Mass., Dec. 21, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced the closing of its underwritten public offering of securities for...

News Article | December 26, 2016
Site: www.prnewswire.com

MARLBOROUGH, Mass., Dec. 26, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present at the 9th Annual Biotech Showcase™ 2017 being he...

Loading RXi Pharmaceuticals collaborators
Loading RXi Pharmaceuticals collaborators